FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

Mail Online -

Mail Online—June 4 (Reuters) - Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar version of Amgen Inc's drug, Neulasta, to market, with U.S....

FDA approves Mylan drug as first biosimilar to Amgen's Neulasta. (Reuters) - Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar version of Amgen Inc's drug, Neulasta, to market, with U.S. health regulators approving its version of the blockbuster infection-fighting treatment.